The latest attempt focuses on liraglutide, an older, once-daily injectable product in Novo Nordisk's GLP-1 agonist franchise sold as Victoza and Xultophy for diabetes and Saxenda for obesity.

While more research is necessary, Duah said that Zepbound (tirzepatide) may be more effective than Wegovy (semaglutide) or Saxenda (liraglutide) for weight loss. A comprehensive 2024 research ...

The FDA says the okay to use Victoza (liraglutide) in paediatric patients aged 10 or over comes “at a time when an increasing number of children are being diagnosed with this disease.” ...

In patients with high-risk heart failure (HF) with reduced ejection fraction, the GLP-1 agonist liraglutide did not improve death rate or rate of hospitalization, according to results from the FIGHT ...

Therefore, the purpose of this study is to investigate the maintenance of weight loss and immunometabolic health outcomes after diet-induced weight loss followed by 1-year treatment with a ...